Morgan Stanley
AKBA icon

Morgan Stanley’s Akebia Therapeutics AKBA Stock Holding History

Morgan Stanley’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$808K Sell
581,327
-647,489
-53% -$890K ﹤0.01% 5255
2025
Q4 		$1.98M Sell
1,228,816
-3,086,385
-72% -$6.46M ﹤0.01% 4816
2025
Q3 		$11.8M Sell
4,315,201
-1,024,453
-19% -$3.41M ﹤0.01% 3396
2025
Q2 		$19.4M Buy
5,339,654
+2,658,456
+99% +$7.3M ﹤0.01% 2840
2025
Q1 		$5.15M Buy
2,681,198
+891,147
+50% +$1.82M ﹤0.01% 3899
2024
Q4 		$3.4M Buy
1,790,051
+701,159
+64% +$1.22M ﹤0.01% 4305
2024
Q3 		$1.44M Buy
1,088,892
+325,560
+43% +$435K ﹤0.01% 4842
2024
Q2 		$779K Sell
763,332
-25,043
-3% -$30.9K ﹤0.01% 5105
2024
Q1 		$1.44M Sell
788,375
-559,183
-41% -$894K ﹤0.01% 4759
2023
Q4 		$1.67M Buy
1,347,558
+935,729
+227% +$954K ﹤0.01% 5020
2023
Q3 		$469K Buy
411,829
+37,205
+10% +$47.8K ﹤0.01% 5193
2023
Q2 		$343K Sell
374,624
-269,493
-42% -$260K ﹤0.01% 5406
2023
Q1 		$361K Buy
644,117
+302,988
+89% +$231K ﹤0.01% 5439
2022
Q4 		$197K Sell
341,129
-6,389
-2% -$2K ﹤0.01% 5676
2022
Q3 		$110K Sell
347,518
-309,021
-47% -$121K ﹤0.01% 6027
2022
Q2 		$232K Sell
656,539
-339,175
-34% -$142K ﹤0.01% 5821
2022
Q1 		$714K Sell
995,714
-200,500
-17% -$429K ﹤0.01% 5191
2021
Q4 		$2.7M Sell
1,196,214
-277,291
-19% -$756K ﹤0.01% 4332
2021
Q3 		$4.24M Sell
1,473,505
-1,186,868
-45% -$3.39M ﹤0.01% 3907
2021
Q2 		$10.1M Sell
2,660,373
-680,337
-20% -$2.29M ﹤0.01% 2973
2021
Q1 		$11.3M Buy
3,340,710
+3,080,193
+1,182% +$11.1M ﹤0.01% 2521
2020
Q4 		$729K Sell
260,517
-940,739
-78% -$2.75M ﹤0.01% 4843
2020
Q3 		$3.01M Buy
1,201,256
+986,634
+460% +$8.66M ﹤0.01% 3251
2020
Q2 		$2.91M Buy
214,622
+37,240
+21% +$385K ﹤0.01% 3219
2020
Q1 		$1.35M Sell
177,382
-808,653
-82% -$6.29M ﹤0.01% 3713
2019
Q4 		$6.23M Sell
986,035
-33,635
-3% -$160K ﹤0.01% 2945
2019
Q3 		$4M Sell
1,019,670
-188,721
-16% -$809K ﹤0.01% 3112
2019
Q2 		$5.85M Sell
1,208,391
-119,137
-9% -$678K ﹤0.01% 2757
2019
Q1 		$10.9M Buy
1,327,528
+293,620
+28% +$2.01M ﹤0.01% 1963
2018
Q4 		$5.72M Sell
1,033,908
-853,528
-45% -$6.68M ﹤0.01% 2737
2018
Q3 		$16.7M Buy
1,887,436
+496,069
+36% +$4.44M ﹤0.01% 1862
2018
Q2 		$13.9M Buy
1,391,367
+217,504
+19% +$2.18M ﹤0.01% 2015
2018
Q1 		$11.2M Buy
1,173,863
+406,975
+53% +$5.69M ﹤0.01% 2244
2017
Q4 		$11.4M Buy
766,888
+54,516
+8% +$904K ﹤0.01% 2278
2017
Q3 		$14M Buy
712,372
+9,667
+1% +$149K ﹤0.01% 1933
2017
Q2 		$10.1M Sell
702,705
-167,737
-19% -$2.13M ﹤0.01% 2183
2017
Q1 		$8.01M Buy
870,442
+55,369
+7% +$541K ﹤0.01% 2419
2016
Q4 		$8.48M Buy
815,073
+477,567
+141% +$4.11M ﹤0.01% 2435
2016
Q3 		$3.05M Buy
337,506
+116,001
+52% +$986K ﹤0.01% 3148
2016
Q2 		$1.66M Sell
221,505
-12,243
-5% -$107K ﹤0.01% 3580
2016
Q1 		$2.11M Buy
233,748
+134,602
+136% +$1.09M ﹤0.01% 3308
2015
Q4 		$1.28M Sell
99,146
-13,763
-12% -$140K ﹤0.01% 3866
2015
Q3 		$1.09M Buy
112,909
+64,722
+134% +$594K ﹤0.01% 4035
2015
Q2 		$496K Sell
48,187
-7,638
-14% -$65.2K ﹤0.01% 4713
2015
Q1 		$620K Sell
55,825
-67,710
-55% -$721K ﹤0.01% 4501
2014
Q4 		$1.44M Sell
123,535
-179,377
-59% -$2.57M ﹤0.01% 3840
2014
Q3 		$6.7M Sell
302,912
-93,937
-24% -$2.16M ﹤0.01% 2378
2014
Q2 		$11M Buy
+396,849
New +$9.55M ﹤0.01% 1947

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Morgan Stanley's AKBA Position: Q1 2026 in Review

Morgan Stanley reduced its Akebia Therapeutics (AKBA) stake by 53% in Q1 2026, selling an estimated $890K and leaving 581,327 shares worth $808K. The position accounts for ﹤0.01% of the portfolio, ranked #5255.

Morgan Stanley first reported a position in AKBA in Q2 2014 and has held it in 48 quarters since. The position peaked at $19.4M in Q2 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Morgan Stanley held 581,327 shares of Akebia Therapeutics worth $808K as of Q1 2026.
  • Morgan Stanley sold 647,489 Akebia Therapeutics shares in Q1 2026, an estimated $890K.
  • Akebia Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5255 holding.
  • Morgan Stanley first reported a position in Akebia Therapeutics in Q2 2014 and has held it in 48 quarters since.
  • Morgan Stanley's Akebia Therapeutics position peaked at $19.4M in Q2 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.